OCE Oncology News
A monthly newsletter for oncology/hematology fellows, junior faculty and scientists
A monthly newsletter for oncology/hematology fellows, junior faculty and scientists
AACR is hosting a workshop with the FDA on January 16, 2025, to discuss the considerations for routine testing of DPD deficiency before treatment with…
Stomach Cancer statistics
Almost half of all novel medications approved by the U.S. Food and Drug Administration (FDA) are orphan drugs. Below is the list of important regulatory…
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
SEER*Explorer provides access to SEER cancer statistics and detailed statistics for a cancer site by gender, race, calendar year, age, and for a selected number…
An abstract is unavailable.
The phase 1 study found that INCB057643, as monotherapy or in combination with ruxolitinib, was generally well tolerated in patients with relapsed or refractory MF.
This communication is part of the Communications Pilot to Enhance the Medical Device Recall Program
Take this survey powered by surveymonkey.com. Create your own surveys for free.